Altimmune Statistics
Total Valuation
Altimmune has a market cap or net worth of $477.88 million. The enterprise value is $295.82 million.
| Market Cap | 477.88M |
| Enterprise Value | 295.82M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, before market open.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Altimmune has 70.90 million shares outstanding. The number of shares has increased by 41.25% in one year.
| Shares Outstanding | 70.90M |
| Shares Change (YoY) | +41.25% |
| Shares Change (QoQ) | +21.03% |
| Owned by Insiders (%) | 0.78% |
| Owned by Institutions (%) | 63.33% |
| Float | 70.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,165.56 |
| Forward PS | n/a |
| PB Ratio | 2.76 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 721.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.55, with zero debt.
| Current Ratio | 16.55 |
| Quick Ratio | 16.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,727.44 |
Financial Efficiency
Return on equity (ROE) is -54.20% and return on invested capital (ROIC) is -58.38%.
| Return on Equity (ROE) | -54.20% |
| Return on Assets (ROA) | -49.50% |
| Return on Capital (ROIC) | -58.38% |
| Revenue Per Employee | $6,949 |
| Profits Per Employee | -$1.57M |
| Employee Count | 59 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +95.36% in the last 52 weeks. The beta is 0.10, so Altimmune's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | +95.36% |
| 50-Day Moving Average | 7.09 |
| 200-Day Moving Average | 6.96 |
| Relative Strength Index (RSI) | 49.08 |
| Average Volume (20 Days) | 5,066,104 |
Short Selling Information
The latest short interest is 23.14 million, so 32.64% of the outstanding shares have been sold short.
| Short Interest | 23.14M |
| Short Previous Month | 23.47M |
| Short % of Shares Out | 32.64% |
| Short % of Float | 32.88% |
| Short Ratio (days to cover) | 8.86 |
Income Statement
In the last 12 months, Altimmune had revenue of $410,000 and -$92.77 million in losses. Loss per share was -$1.61.
| Revenue | 410,000 |
| Gross Profit | 410,000 |
| Operating Income | -100.96M |
| Pretax Income | -92.77M |
| Net Income | -92.77M |
| EBITDA | -91.79M |
| EBIT | -92.73M |
| Loss Per Share | -$1.61 |
Balance Sheet
The company has $182.07 million in cash and no debt, giving a net cash position of $182.07 million or $2.57 per share.
| Cash & Cash Equivalents | 182.07M |
| Total Debt | n/a |
| Net Cash | 182.07M |
| Net Cash Per Share | $2.57 |
| Equity (Book Value) | 172.94M |
| Book Value Per Share | 2.44 |
| Working Capital | 176.18M |
Cash Flow
In the last 12 months, operating cash flow was -$72.76 million and capital expenditures $4,000, giving a free cash flow of -$72.76 million.
| Operating Cash Flow | -72.76M |
| Capital Expenditures | 4,000 |
| Free Cash Flow | -72.76M |
| FCF Per Share | -$1.03 |
Margins
Gross margin is 100.00%, with operating and profit margins of -24,625.37% and -22,626.10%.
| Gross Margin | 100.00% |
| Operating Margin | -24,625.37% |
| Pretax Margin | -22,626.10% |
| Profit Margin | -22,626.10% |
| EBITDA Margin | -22,388.54% |
| EBIT Margin | -22,617.80% |
| FCF Margin | -17,745.37% |
Dividends & Yields
Altimmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -41.25% |
| Shareholder Yield | -41.25% |
| Earnings Yield | -19.41% |
| FCF Yield | -15.22% |
Analyst Forecast
The average price target for Altimmune is $18.80, which is 178.93% higher than the current price. The consensus rating is "Buy".
| Price Target | $18.80 |
| Price Target Difference | 178.93% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 290.58% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on September 14, 2018. It was a reverse split with a ratio of 1:30.
| Last Split Date | Sep 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
Altimmune has an Altman Z-Score of 14.45 and a Piotroski F-Score of 2.
| Altman Z-Score | 14.45 |
| Piotroski F-Score | 2 |